Chengdu Olymvax Biopharmaceuticals Inc.

成都欧林生物科技股份有限公司

Develops, manufactures and commercializes vaccines in China, focusing on superbug and adult vaccines. Its commercialized products include an adsorbed tetanus vaccine, which ranked first in China's adsorbed tetanus vaccine market with ~98.8% share in 2025 (per CIC), alongside Hib and AC conjugate vaccines.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Single product, business line or region
• Government or SOE customers and tenders
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Key long-term agreements
• Seasonality and cyclicality
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Non-recurring gains and losses
• Chapter 18A biotech
• Sanctioned countries and export controls